FDG-PET and PET-CT are increasingly important in staging, evaluating treatment response and monitoring for relapse of childhood lymphoma, replacing gallium scans for the assessment of metabolically active disease.
These data provide a strong case for continuation of maintenance treatment to beyond one year after a first episode of psychosis, but we also acknowledge that the clinical decision for maintenance treatment must be made in an individualised manner taking into consideration factors such as side effects and the availability of effective monitoring for relapse.
According to study protocol, he will be followed for 1 year posttreatment to monitor for relapse.
A repeated blood smear examination at 7 and 28 days after completion of therapy is recommended to monitor for relapse of severe falciparum malaria [ 31].
The amount of benzodiazepines prescribed to the patient should be limited, and the patient should be closely monitored for relapse or nonmedical use of benzodiazepines or other medications.
This method, termed 'personalized analysis of rearranged ends' (PARE), identified tumor-specific biomarkers that can be used to monitor response to therapy, assess residual disease and/or monitor for relapse.
As a result, there is mounting interest in learning whether NGR should be the goal for people with prediabetes and, further, whether they should be monitored for relapse to prediabetes with escalating and earlier intervention instituted as needed to maintain NGR (9).
Interestingly, in identification of hepatocellular carcinoma, higher sensitivity and specificity has been shown for serum GPC3 than for AFP (289), which raises the possibility of a similar noninvasive test for YST, of particular interest for monitoring patients for relapse.
The tissues were obtained after orchidectomy for testicular cancer (adult testis and testicular tumours) from spontaneous abortions/miscarriages (foetal tissues) and from control biopsies to monitor for relapses of acute leukaemia (pre-pubertal testis samples).
Methods for earlier detection of recurrent disease already exist, but to date there has been no identified benefit of monitoring for distant relapse since metastatic disease remains essentially uncurable.
Some investigators have shown that testing for DNA alterations in peripheral blood has great potential, especially for early detection and diagnosis and for monitoring for a relapse during follow-up (Chen et al, 1996; Nawroz et al, 1996; Sozzi et al, 1999, 2001; Cuda et al, 2000; Nunes et al, 2001).
